These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7723558)

  • 1. Antituberculous therapy and acute liver function.
    FitzGerald JM
    Lancet; 1995 May; 345(8958):1172. PubMed ID: 7723558
    [No Abstract]   [Full Text] [Related]  

  • 2. Antituberculous therapy and acute liver failure.
    Caplin M; Thompson N; Hamilton M; McIntyre N; Burroughs A
    Lancet; 1995 May; 345(8958):1171. PubMed ID: 7786346
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison between two strategies for monitoring hepatic function during antituberculous therapy.
    Singanayagam A; Sridhar S; Dhariwal J; Abdel-Aziz D; Munro K; Connell DW; George PM; Molyneaux PL; Cooke GS; Burroughs AK; Lalvani A; Wickremasinghe M; Kon OM
    Am J Respir Crit Care Med; 2012 Mar; 185(6):653-9. PubMed ID: 22198973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
    Grymiński J; Lyczewska J; Styszewska H; Walczak J
    Pol Med J; 1970; 9(3):635-44. PubMed ID: 5452841
    [No Abstract]   [Full Text] [Related]  

  • 6. Are antitubercular drugs prescribed correctly and scientifically?
    Sahoo RC
    J Assoc Physicians India; 1994 Apr; 42(4):349-50. PubMed ID: 7860579
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early monitoring for detection of antituberculous drug-induced hepatotoxicity.
    Lee CM; Lee SS; Lee JM; Cho HC; Kim WS; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ
    Korean J Intern Med; 2016 Jan; 31(1):65-72. PubMed ID: 26767859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation and antituberculosis drug-induced liver injury.
    Devarbhavi H
    Am J Respir Crit Care Med; 2012 Aug; 186(4):387-8; author reply 388-9. PubMed ID: 22896595
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatotoxicity of antituberculous drugs.
    Rao NK; Wadia RS; Karve SR; Grant KB
    J Assoc Physicians India; 1982 May; 30(5):295-8. PubMed ID: 7169440
    [No Abstract]   [Full Text] [Related]  

  • 11. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe acute hepatitis associated with morphazinamide therapy.
    Zavaglia C; Mondazzi L; Fesce E; Iamoni G; Lanzani F; Ideo G
    J Hepatol; 1996 Dec; 25(6):1001. PubMed ID: 9007735
    [No Abstract]   [Full Text] [Related]  

  • 13. Liver function testing in African patients on treatment for tuberculosis.
    Davies PD
    East Afr Med J; 1985 Jul; 62(7):486-90. PubMed ID: 4076028
    [No Abstract]   [Full Text] [Related]  

  • 14. [Liver damage caused by the continued use of chemotherapy of pulmonary tuberculosis].
    Yamazaki M; Endo K; Noguchi T; Nakano M
    Iryo; 1966 Apr; 20(4):347-53. PubMed ID: 5974193
    [No Abstract]   [Full Text] [Related]  

  • 15. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of hyperacute hepatotoxicity in response to tuberculosis therapy.
    Hercus CG; Khoo JK; Jones TE
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1709-10. PubMed ID: 23131275
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rational use of hepato-protectants in the prophylaxis and treatment of anti-tuberculosis drug-induced hepatotoxicity].
    Gu J; Xiao HP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):767-9. PubMed ID: 24433806
    [No Abstract]   [Full Text] [Related]  

  • 18. Side effects of antituberculosis drugs.
    Mohan A; Sharma SK
    Am J Respir Crit Care Med; 2004 Apr; 169(7):882-3. PubMed ID: 15044223
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of British Thoracic Society and American Thoracic Society reintroduction guidelines for anti-tuberculous therapy induced liver injury.
    Zuberi BF; Zuberi FF; Bader N; Alvi H; Salahuddin J
    J Pak Med Assoc; 2014 Aug; 64(8):896-9. PubMed ID: 25252514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinic and pathogenesis of drug hepatitis].
    Mardare G
    Rev Med Chir Soc Med Nat Iasi; 1982; 86(1):43-5. PubMed ID: 25591247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.